NL-OMON41865已完成不适用
A phase 1 randomized, double-blind, placebo-controlled, maximum tolerated dose escalation, safety, tolerability and pharmacokinetic adaptive study of RAD1901 administered to healthy postmenopausal women - RAD1901 MTD study in healthy postmenopausal women
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 68
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •healthy post-menopausal female subjects
- •40-75 yrs, inclusive
- •BMI: 18.0 - 30.0 kg/m2, inclusive
排除标准
- •Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS. In case of participation in another drug study within 90 days before the start of this study or being a blood donor within 60 days from the start of the study. In case of donating more than 1.5 liters of blood in the 10 months prior the start of this study
研究者
相似试验
招募中
1 期
A Phase 1 Study of AP02 (Nintedanib Solution for Inhalation) Delivered via the PARI eFlow® Nebulizer System to Evaluate the Safety, Tolerability, and Pharmacokinetics of AP02 in Healthy Volunteers (AP02-002)Respiratory - Other respiratory disorders / diseasesIdiopathic Pulmonary FibrosisACTRN12624000825550Avalyn Pharma, Inc.68
招募中
1 期
A Phase 1 randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetics of single ascending doses and multiple ascending doses of SION-451 in healthy participantsHuman Genetics and Inherited Disorders - Cystic fibrosisCystic FibrosisACTRN12624000849594Sionna Therapeutics, Inc96
尚未招募
1 期
A Phase 1 study to evaluate the safety and pharmacokinetics of single and multiple doses of SION-719 in healthy participantsHuman Genetics and Inherited Disorders - Cystic fibrosisRespiratory - Other respiratory disorders / diseasesCystic FibrosisACTRN12624000739516Sionna Therapeutics, Inc96
招募中
1 期
Ascending multiple doses of a novel Interluken(IL-1) agonist administered to healthy subjectsauto-immune inflammatory diseaseInflammatory and Immune System - Rheumatoid arthritisACTRN12610000287033Hutchison MediPharma24
进行中（未招募）
1 期
A study to investigate Thetanix (Bacteroides thetaiotaomicron) in young people aged 16 to 18 years with stable Crohn's diseaseCrohn's disease in young personsMedDRA version: 20.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disordersEUCTR2014-005666-29-GB4D Pharma18